STOCK TITAN

Soligenix Inc - SNGX STOCK NEWS

Welcome to our dedicated page for Soligenix news (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix stock.

Overview

Soligenix Inc (SNGX) is a late-stage biopharmaceutical company based in the United States that specializes in developing and commercializing innovative products addressing unmet medical needs. With a focus on orphan diseases, inflammation, oncology, and biodefense, the company leverages advanced technologies to create therapeutics and vaccine candidates designed for rare and niche medical conditions.

Business Segments and Product Portfolio

Soligenix operates two distinct business segments:

  • Specialized BioTherapeutics: This segment is dedicated to developing novel therapies for rare disorders and orphan diseases. Among its flagship programs is a photodynamic therapy that employs synthetic hypericin for the treatment of cutaneous T-cell lymphoma (CTCL). The company utilizes safe, visible light activation to trigger the therapeutic effects of its compounds, thereby reducing the risks associated with traditional treatments.
  • Public Health Solutions: Focused on biodefense and vaccine development, this segment includes programs to develop vaccines for ricin toxin exposure, filovirus infections such as those caused by Ebola and Marburg viruses, and other emerging infectious diseases. The development of thermostabilized vaccine formulations via its proprietary technology platform enhances their resilience and accessibility even in challenging storage environments.

Innovative Therapeutic Approaches

At its core, Soligenix is an innovator in biopharmaceutical research. The company’s approach emphasizes:

  • Orphan Drug Focus: Addressing diseases with significant unmet medical needs, ensuring that even rare conditions receive the focus required for treatment breakthroughs.
  • Advanced Photodynamic Therapy: Through programs such as HyBryte, Soligenix demonstrates the effective use of synthetic hypericin combined with visible light activation. This method offers a potent, targeted treatment for CTCL, minimizing systemic exposure and potential side effects inherent in conventional treatments.
  • Heat-Stabilized Vaccine Platforms: Utilizing a unique combination of GRAS excipients and lyophilization, the company manufactures vaccines that are stable at ambient temperatures, a critical factor for both military and civilian biodefense applications.

Market Position and Competitive Landscape

Operating within a highly specialized niche, Soligenix distinguishes itself with its dual focus on orphan therapeutics and biodefense. The company continues to advance clinical trials with clear protocols and has secured orphan drug and fast track designations from prominent regulatory authorities. By leveraging government grants and non-dilutive funding, Soligenix is well positioned to overcome the challenges associated with clinical validation and commercialization in competitive markets.

Intellectual Property and Strategic Collaborations

Soligenix has built a robust intellectual property portfolio that encompasses novel synthesis methods and treatments for rare diseases. Strategic manufacturing collaborations further enhance its capabilities in scaling production and ensuring quality, critical factors for commercial success. These alliances help solidify its market role and support ongoing research, clinical trials, and regulatory activities.

Commitment to Unmet Medical Needs

The company is unwavering in its commitment to provide therapies where options are limited. Whether it is through innovative photodynamic treatment for CTCL or next-generation vaccine platforms aimed at biodefense, Soligenix prioritizes technological advancement and patient safety. The detailed clinical trial programs and continuous research efforts underscore its expertise and dedication within the biopharmaceutical field.

Conclusion

In summary, Soligenix Inc establishes its significance through a combination of advanced scientific methodologies and a focused strategy on rare diseases with high unmet needs. Its dual business segments not only contribute to a diversified product pipeline but also reinforce its authorization as a relevant player in the competitive biopharmaceutical landscape. Investors and industry experts can view Soligenix as a company that merges solid clinical data with a strategic vision for addressing health challenges that many others overlook.

Rhea-AI Summary

On May 4, 2021, Soligenix (Nasdaq: SNGX) announced positive results from the Phase 3 FLASH study concerning HyBryte™ (SGX301) for treating cutaneous T-cell lymphoma (CTCL). During the Society for Investigative Dermatology meeting, data revealed that 49% of patients achieved a significant reduction in lesions after 18 weeks. HyBryte™ demonstrated fewer severe side effects than current therapies and showed a low 5% drop-out rate due to adverse events. The study marked the largest of its kind, suggesting HyBryte™ could fulfill a critical need for safer CTCL treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
none
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced a successful presentation on its CiVax™ COVID-19 vaccine program at the Annual Conference on Vaccinology Research on April 26-27, 2021. The presentation highlighted the vaccine's potent immunogenicity in mice and non-human primates, utilizing heat-stabilization technology and the CoVaccine HT™ adjuvant, which allows for dose-sparing and ambient temperature storage. This innovative approach may facilitate rapid global vaccine distribution. The project is supported by a grant from the National Institutes of Health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
none
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced expanded data on its photodynamic therapy HyBryte™ (SGX301) for cutaneous T-cell lymphoma (CTCL) during the American Academy of Dermatology meeting. The Phase 3 FLASH study showed a 40% treatment response after 12 weeks and 49% after 18 weeks, with serious adverse events at just 2.4%. HyBryte™ demonstrated significant efficacy with a non-mutagenic mechanism, avoiding long-term actinic skin damage. This pivotal trial is the largest of its kind for CTCL, indicating potential as a safer front-line therapy compared to existing treatments. Regulatory approval is being sought for commercial launch.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.27%
Tags
none
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced planned presentations at upcoming conferences showcasing their innovative therapies. The focus will be on HyBryte™ (SGX301), a treatment for cutaneous T-cell lymphoma (CTCL), highlighting results from the Phase 3 FLASH study, and updates on their CiVax™ COVID-19 vaccine program. HyBryte™ has shown significant efficacy, with a 16% reduction in lesions during the first treatment cycle, compared to 4% in placebo. HyBryte™ is a first-in-class therapy using synthetic hypericin with no systemic absorption, aiming for regulatory approval in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.7%
Tags
none
-
Rhea-AI Summary

Soligenix (Nasdaq: SNGX) has received conditional acceptance from the U.S. FDA for the brand name HyBryte™ for its novel treatment SGX301, intended for early-stage cutaneous T-cell lymphoma (CTCL). This milestone supports Soligenix's goal of U.S. commercialization, with plans to submit a rolling new drug application in Q2 2021. SGX301 has been designated as an Orphan Drug and received Fast Track designations from the FDA, emphasizing its potential impact on patients with this rare disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
none
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) reported its 2020 financial results, revealing revenues of $2.4 million, down from $4.6 million in 2019. The company experienced a net loss of $17.7 million, a significant increase due to high R&D costs related to its Phase 3 clinical trials for SGX301 and SGX942. Soligenix successfully completed the Phase 3 FLASH trial for SGX301, paving the way for a rolling NDA submission in 2Q 2021. With over $30 million in cash and non-dilutive funding, the firm is poised for growth, targeting over $90 million in U.S. annual net sales for SGX301, amid partnerships for expanding its market reach.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced preliminary approval for a tax credit from the New Jersey Economic Development Authority, allowing the transfer of approximately $865,000 in net proceeds. This program enables biotechnology firms to convert unused Net Operating Loss Carryovers and R&D Tax Credits into cash. Over 11 years, Soligenix has received about $6.5 million in such funding, supporting its rare disease pipeline. The company is preparing to submit a rolling NDA for SGX301, its first-in-class therapy for cutaneous T-cell lymphoma, projected to achieve annual sales exceeding $90 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
none
-
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced positive progress in pre-clinical studies for its COVID-19 vaccine candidate, CiVax™, highlighting confirmed broad-spectrum immunity through its full-length Spike protein antigens. Research published on bioRxiv shows the vaccine's potential for rapid distribution without cold chain requirements, supported by a $1.5M SBIR grant. Collaborative efforts with the University of Hawaiʻi aim to evaluate immunogenicity in future non-human primate models while addressing logistical challenges in global vaccine distribution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.59%
Tags
clinical trial covid-19
-
Rhea-AI Summary

Soligenix, Inc. (SNGX) provided a corporate update highlighting a positive Phase 3 study of SGX301 for cutaneous T-cell lymphoma, with plans for a new drug application (NDA) submission. The company also reported promising preclinical results for its heat-stable COVID-19 vaccine candidate, CiVax™, while maintaining a strong cash position of over $30 million to support growth. Notably, SGX301's U.S. peak annual sales could exceed $90 million. However, disappointing results from SGX942's Phase 3 trial for oral mucositis raised concerns, as it did not meet statistical significance despite showing biological activity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.2%
Tags
none
Rhea-AI Summary

Soligenix, Inc. (Nasdaq: SNGX) announced that its CEO, Christopher J. Schaber, PhD, will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will be available for on-demand viewing starting February 15 at 9:00 AM EST. Soligenix is advancing its drug application for SGX301, a treatment for cutaneous T-cell lymphoma, following a successful Phase 3 study. The conference offers an opportunity for one-on-one meetings with management, focusing on the company's rare disease pipeline and potential partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.18%
Tags
conferences

FAQ

What is the current stock price of Soligenix (SNGX)?

The current stock price of Soligenix (SNGX) is $2.21 as of April 1, 2025.

What is the market cap of Soligenix (SNGX)?

The market cap of Soligenix (SNGX) is approximately 7.0M.

What is the core focus of Soligenix Inc?

Soligenix Inc is focused on developing and commercializing innovative therapeutics and vaccines targeting rare diseases with significant unmet medical needs, particularly in oncology, inflammation, and biodefense.

How does Soligenix generate revenue?

The company primarily generates revenue through government contracts, grants, and milestone-based funding tied to its clinical trial successes and ongoing development programs within its specialized and public health segments.

What are the main business segments of Soligenix?

Soligenix operates two main segments: Specialized BioTherapeutics, which develops treatments for orphan diseases such as CTCL, and Public Health Solutions, which focuses on biodefense-related vaccine development.

What therapeutic areas does Soligenix focus on?

The company targets multiple therapeutic areas including cutaneous T-cell lymphoma (CTCL), orphan diseases, inflammatory conditions, and biodefense, with products designed to address both clinical and public health challenges.

How does HyBryte™ differentiate itself in treating CTCL?

HyBryte™ employs a novel photodynamic therapy using synthetic hypericin activated by safe, visible light, offering targeted treatment with minimal systemic exposure and a favorable safety profile compared to traditional therapies.

What role does intellectual property play for Soligenix?

Soligenix has established a robust portfolio of patents covering novel synthesis methods and therapeutic applications, which strengthens its competitive position and supports its advanced clinical programs.

How is the company supported financially?

Soligenix benefits from government grants, non-dilutive funding, and strategic partnerships, allowing it to progress in clinical trials and product development while mitigating financial risk.

What are the key technologies used in Soligenix's vaccine programs?

The company uses a proprietary heat stabilization platform, ThermoVax®, which employs GRAS excipients and lyophilization to produce vaccines that are stable at ambient temperatures, enhancing their practical use in biodefense.
Soligenix Inc

Nasdaq:SNGX

SNGX Rankings

SNGX Stock Data

6.97M
2.51M
0.03%
1.22%
4.01%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON